Request Trial
pills-istock-525984851-1
sprng23 / iStockphoto.com
23 May 2018Americas

Lundbeck and Takeda take on Lupin over anti-depressant ANDA

Pharmaceutical companies Lundbeck and Takeda have sued generic drug producer Lupin for infringing a patent directed to anti-depressant medication Trintellix (vortioxetine hydrobromide).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
AI, anxiety, and antibodies: The issues dominating life sciences
26 May 2026   Two days of discussions at LSPN North America revealed an industry grappling with narrower patent claims, global strategy changes, AI disruption and tougher dealmaking conditions.
Americas
How should in-house teams adopt AI? ‘Carefully’, says secrets expert
26 May 2026   Ahead of WIPR Trade Secrets West, Cooley partner Heidi Keefe says that for legal teams, caution—not business pressure—should be the priority.
Americas
Lupin scores another win in kidney drug dispute
22 May 2026   A US appeals court has handed the generic drugmaker victory in a closely watched dispute over a treatment for a serious inherited kidney condition, dealing a setback to its branded rival.


Editor's picks

Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

Editor's picks

Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026
Americas
Penile implant maker’s $17m trade secret award unravels
20 April 2026
Biotechnology
Closing the women's health gap offers ‘benefits for all’
7 April 2026
Europe
European patent offices raise fees
2 April 2026
Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
1 April 2026

More features

Takeda’s China IP head: What pharma is still getting wrong
Boehringer Ingelheim adds ex-Teva executive to patent team
AI, anxiety, and antibodies: The issues dominating life sciences
UPC judge: ‘Expectations of you as a woman are the challenge’
How should in-house teams adopt AI? ‘Carefully’, says secrets expert
Lupin scores another win in kidney drug dispute
Battle over inhaler shape ends badly for Boehringer
Chinese medtech company fined by UPC over injunction breaches